AWM Investment Company Inc. Has $21.16 Million Stock Position in ASP Isotopes Inc. $ASPI

Key Points

• AWM Investment Company Inc. has increased its stake in ASP Isotopes Inc. by 6.2%, now owning approximately 4.5 million shares worth $21.2 million, making it the firm's fifth largest holding.
• Multiple institutional investors, including Price T Rowe Associates and SBI Securities, have also recently increased their stakes in ASP Isotopes, indicating growing interest in the company's stock.
• ASP Isotopes reported a revenue of $1.20 million in its latest quarter, missing analyst estimates of $1.60 million and posting an earnings per share (EPS) of -$1.03.

AWM Investment Company Inc. boosted its holdings in ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 6.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,511,186 shares of the company's stock after acquiring an additional 265,000 shares during the period. ASP Isotopes comprises about 2.9% of AWM Investment Company Inc.'s investment portfolio, making the stock its 5th biggest holding. AWM Investment Company Inc. owned about 6.01% of ASP Isotopes worth $21,157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Two Sigma Investments LP acquired a new position in shares of ASP Isotopes during the fourth quarter valued at about $1,980,000. Nuveen Asset Management LLC raised its position in ASP Isotopes by 672.1% in the fourth quarter. Nuveen Asset Management LLC now owns 413,346 shares of the company's stock worth $1,872,000 after purchasing an additional 359,811 shares in the last quarter. Nuveen LLC acquired a new stake in shares of ASP Isotopes during the first quarter worth approximately $615,000. Rovida Investment Management Ltd grew its stake in shares of ASP Isotopes by 59.8% during the first quarter. Rovida Investment Management Ltd now owns 350,000 shares of the company's stock valued at $1,620,000 after purchasing an additional 131,028 shares during the last quarter. Finally, Two Sigma Advisers LP bought a new position in ASP Isotopes in the fourth quarter valued at approximately $402,000. Institutional investors own 16.80% of the company's stock.

Insider Buying and Selling at ASP Isotopes

In other news, Director Duncan Moore sold 75,000 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $9.28, for a total value of $696,000.00. Following the transaction, the director owned 994,553 shares in the company, valued at $9,229,451.84. This represents a 7.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 21.40% of the stock is owned by company insiders.

ASP Isotopes Stock Performance

NASDAQ ASPI traded up $0.17 during trading hours on Monday, reaching $8.38. 2,019,397 shares of the company were exchanged, compared to its average volume of 3,216,387. The stock has a market capitalization of $769.84 million, a P/E ratio of -13.72 and a beta of 3.36. The company has a quick ratio of 14.56, a current ratio of 14.72 and a debt-to-equity ratio of 3.53. The business's 50 day simple moving average is $9.00 and its 200-day simple moving average is $7.04. ASP Isotopes Inc. has a 1 year low of $2.12 and a 1 year high of $11.68.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. On average, equities research analysts expect that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group lifted their price target on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $7.75.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.